Pre-earnings brief
Reports
Mon, Mar 14, 2022
Est. EPS
—
Est. revenue
—
Implied move
±2.7%
EPS beat rate
38%
Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology. This innovative approach aims to treat a range of genetic diseases, making it a significant player in the health care sector, particularly in gene therapy.
Last quarter
In Q2-2026, Beam reported an EPS loss of $-1.18, which was worse than the expected loss of $-1.00. Despite the miss, the stock rose by 9.42% the following day, indicating some investor optimism.
Management promises and guidance
EPS beat streak
0Q
EPS beat rate
38%
Avg EPS surprise
+32.58%
Avg 1-day reaction
-1.49%
Overall expectations for Beam's upcoming earnings report are cautious, given the recent earnings misses and lack of analyst estimates. Investors are looking for signs of progress in clinical trials and financial management.
Bull case
If Beam shows significant advancements in its clinical trials and manages to reduce its cash burn, it could lead to a positive reassessment of its growth potential, driving the stock higher.
Bear case
Conversely, if the company reports higher-than-expected losses or delays in its clinical trials, it could further erode investor confidence and lead to a decline in the stock price.
The print will turn on these.
Q1
What is the current status of Beam's clinical trials and any anticipated timelines for results?
The market will closely watch this as positive trial results could significantly boost investor confidence and stock performance.
Q2
How is Beam managing its cash burn rate, and what are the projections for the next quarter?
Understanding the cash burn rate is critical for assessing the company's financial health and its ability to fund ongoing operations and research.
Est. EPS
—
Est. Rev
—
Impl. Move
—
Why consensus could be wrong
The market may be underestimating Beam's potential for clinical trial success, which could lead to a stronger-than-expected performance this quarter.
Supporting evidence
The recent stock price increase after a disappointing EPS suggests underlying investor optimism.
Options pricing indicates a low expected move, which may not reflect the potential volatility from clinical trial updates.
Key risk
If clinical trial results exceed expectations, it could significantly shift market sentiment.
Pre-commit to what would confirm each case.
This quarter's focus is on Beam's financial management and progress in its clinical pipeline, which are crucial for its future growth.
Bull confirmed if
Demonstrating a significant reduction in cash burn while advancing clinical trials could confirm the bull case.
Bear confirmed if
An increase in cash burn or delays in clinical trial progress would support the bear case.
What the market is pricing for the move.
Implied Move
±2.98%
Historical Avg
±7.34%
The options market is pricing in a relatively modest move for Beam's stock, suggesting that investors are uncertain about the upcoming earnings report.
Options are pricing a 2.98% move, but the stock has averaged a 7.34% move over the last eight quarters, indicating a cheaper setup.
ATM IV
0.6%
30d HV
51.1%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing cheap setup in Health Care
Fade rate: 12 of 30 (40%)
This setup has occurred 30 times across Health Care in the last 2 years. 12 of 30 faded and 18 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 4.6%, with a raw directional average of +2.2% (modestly positive historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Beam beats expectations and raises guidance, history suggests a positive reaction, with an average 1-day move of +2.90%.
In line / cautious
If results are in line but management provides cautious commentary, the stock may see a muted reaction as investors assess the outlook.
Miss
Should Beam miss expectations again, history suggests a potential downside move of -4.12%, which could further impact investor sentiment.
The lines on the call that would change the story.